Business

Major Milestone Treatment Completed in P3 Trial for CLBP

Major Milestone Treatment Completed in P3 Trial for CLBP

Mesoblast LimitedAugust 16, 20265

Major Milestone Treatment Completed in P3 Trial for CLBP

About this update from Mesoblast Limited

Mesoblast Limited has released a press release. View Attachment

View stock analysis, news, and events for Mesoblast Limited

More from Mesoblast Limited

Mesoblast Reports Substantial Revenue Growth to US$120M

August 26, 2026

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

July 29, 2026

All Mesoblast Limited news →